Vericel Corporation (VCEL) Stock Price & How to Invest

Vericel Corporation is a Cambridge, Massachusetts commercial-stage biopharma focused on advanced cell therapies for sports medicine and severe burn care. Its lead product, MACI, is an autologous cultured chondrocyte implant that grows a patient's own cartilage cells on a collagen membrane to repair symptomatic knee cartilage defects, and it anchors roughly 85% of revenue. The burn-care franchise adds Epicel, a permanent skin replacement for severe burns, and NexoBrid, an enzymatic agent that removes dead burn tissue, the latter supported by a multi-year BARDA procurement agreement.

The investment picture is a profitable, self-funding growth company rather than a speculative biotech. Trailing-twelve-month revenue is around $306M (through June 2026) with about $24M of net income, gross margins near 73-75%, roughly $56M of trailing free cash flow, and about $227M of cash and investments with no debt per the company. Q2 2026 revenue rose about 22% to $77.5M (MACI $65.5M, up 23%; burn care $12.0M, up 22%), the company swung to a small GAAP profit, and it raised full-year revenue guidance to $330-340M while authorizing a $200M share repurchase program. The 2026 story centers on a newly FDA-approved MACI manufacturing facility that expands capacity, a UK marketing application now filed with the MHRA, and continued double-digit growth. The tension is valuation: at about $40 a share (October 16, 2026) the stock trades near 6.7x sales and about 47x forward earnings, so the market is already pricing in years of execution, even after a roughly 13% pullback over the past three months.

The stock trades at a rich multiple (about 6.7x sales, a trailing P/E near 85x and a forward P/E near 47x), so any growth slowdown or quarterly miss can trigger sharp drawdowns, as the Q1 2026 GAAP loss reminded investors; the shares fell about 13% over the three months to mid-October 2026, and Truist trimmed its target to $52 from $58 in October. Results are seasonal, with a large share of profit in the fourth quarter, so the Q3 report on November 5, 2026 (consensus about $0.06 of EPS on ~$78M of revenue) can look soft against the full-year guide. Revenue is heavily concentrated in a single product, MACI, and depends on elective orthopedic procedure volumes that can soften in a weak economy. Reimbursement changes, surgeon-adoption pace, and the complexity of a personalized cell-manufacturing supply chain are ongoing execution risks. Larger orthopedics players such as Smith+Nephew, Stryker and Arthrex could pressure the broader cartilage-repair space over time. Burn-care revenue can be lumpy and partly dependent on government contracts.

7 analysts publish price targets on VCEL, averaging $59.71 against a $40.13 price as of October 2026, or +48.8%. The published targets run from $52.00 to $72.00, a moderate spread, and the ratings split 7 buy, 1 hold, 0 sell. Over the last six months there have been 5 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full VCEL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Vericel Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. MACI franchise growth and label expansion. MACI is the core driver, growing revenue in the low-to-mid 20% range (up 23% to $65.5M in Q2 2026) with a large addressable knee-cartilage-defect population and limited direct cell-therapy competition. The most optimistic published target, $72.00, assumes this works close to its best case.

The case against. The stock trades at a rich multiple (about 6.7x sales, a trailing P/E near 85x and a forward P/E near 47x), so any growth slowdown or quarterly miss can trigger sharp drawdowns, as the Q1 2026 GAAP loss reminded investors; the shares fell about 13% over the three months to mid-October 2026, and Truist trimmed its target to $52 from $58 in October. The most pessimistic target, $52.00, is roughly what VCEL is worth if this bites instead.

Read the full bull and bear case on VCEL, including what would have to change to break either one. Walnut is not an investment adviser.

No. Vericel Corporation (VCEL) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Vericel Corporation's investor relations page or your broker.

• Revenue (TTM): ~$306M (+22% YoY in Q2)
• 2026 revenue guidance: ~$330-340M (raised)
• MACI revenue (Q2 2026): ~$65.5M (+23%)
• Net income (TTM): ~$24M
• Gross margin: ~73-75%
• P/E (trailing / forward): ~85x / ~47x
• Market cap: ~$2.1B
• Cash & investments: ~$227M (no debt)

VCEL trades at roughly 6.7x trailing sales, about 85x trailing earnings and about 47x forward earnings, a growth-stock valuation priced on durable 20-30% revenue growth and expanding margins rather than current profits. Q2 2026 revenue rose about 22% to $77.5M with EPS of $0.04 versus a consensus loss, and management raised full-year revenue guidance to $330-340M. Analysts expect about $393M of revenue in 2027; the premium multiple leaves little room for execution missteps.

Other names that sit close to VCEL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get VCEL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so VCEL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VCEL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

VCEL is a durable, growing cell-therapy franchise trading at a rich multiple (about 47x forward earnings), where the debate is valuation and execution, not survival; Q3 2026 results are due November 5.

Whether VCEL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VCEL a buy or a sell?, and where the stock could go from here in the VCEL stock forecast.

For income investors, whether VCEL pays a dividend and how the payout looks is covered in does VCEL pay a dividend? And to weigh VCEL against a peer, read the full side-by-side comparisons: VCEL vs SYK and VCEL vs MRNA.